# **BJGP OPEN**

# Nephrologist referrals of elderly CKD patients in Singapore: A cross-sectional study

Tan, Wei Beng; Szücs, Anna; Burkill, Sarah M; Hui, Ong Shih; Young, Doris; Hoon, Goh Lay

DOI: https://doi.org/10.3399/BJGPO.2021.0155

To access the most recent version of this article, please click the DOI URL in the line above.

Received 20 August 2021 Revised 08 January 2022 Accepted 08 March 2022

© 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/). Published by BJGP Open. For editorial process and policies, see: https://bjgpopen.org/authors/bjgp-open-editorial-process-and-policies

When citing this article please include the DOI provided above.

# **Author Accepted Manuscript**

This is an 'author accepted manuscript': a manuscript that has been accepted for publication in BJGP Open, but which has not yet undergone subediting, typesetting, or correction. Errors discovered and corrected during this process may materially alter the content of this manuscript, and the latest published version (the Version of Record) should be used in preference to any preceding versions

# Nephrologist referrals of elderly CKD patients in Singapore: A cross-sectional study

Wei Beng Tan, MBChB (UK), MRCGP (UK), DRCOG (UK), DGFM (Singapore), GDip (Family Practice Dermatology, Singapore), M. Med (Family Medicine, Singapore).

Job Title: Family Physicians, Associate Consultant, National University Polyclinics, National University Health System.

ORCID number: 0000-0002-6361-6780

Address: National University Polyclinics, 1 Jurong East Street 21, Singapore 609606

Anna Szücs M.D.

Job Title: Postdoctoral Research Fellow, Division of Family Medicine, Department of Medicine, National University of Singapore

ORCID number: 0000-0001-6356-4178

Address: NUS Yong Loo Lin School of Medicine NUHS Tower Block, 1E Kent Ridge Road

Level 11, Singapore 119228

Sarah M Burkill PHD

Job title: Postdoctoral Research Fellow

ORCID number: 0000-0002-8988-4724

Address: Saw Swee Hock School of Public Health, Tahir Foundation Building, National

University of Singapore, 12 Science Drive 2, #10-01, Singapore 117549

Ong Shih Hui, Master in Public Health (Singapore).

Job title: Assistant Director, Regional Health System Office, National University Health System, Singapore.

Address: Alexandra Hospital, Blk 20, 378 Alexandra Rd, Singapore 159964

Doris Young, MBBS (Australia), MD (Australia), FRACGP,

Professor,

Division of Family Medicine, Yong Loo Lin School of Medicine, National University of

Singapore

ORCID number: N/A

Address: NUS Yong Loo Lin School of Medicine NUHS Tower Block, 1E Kent Ridge Road

Level 11, Singapore 119228

Goh Lay Hoon, MBBS (Singapore), M. Med (Family Medicine, Singapore), MClin Epid (Australia)

Job title: Senior Consultant, Department of Family Medicine, National University Health

System, Senior Consultant, National University Polyclinics, Assistant Professor, Division of

Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore

ORCID number: 0000-0003-1536-3050

Address: NUS Yong Loo Lin School of Medicine NUHS Tower Block, 1E Kent Ridge Road

Level 11, Singapore 119228

Solo of the second

Correspondence: wei\_beng\_tan@nuhs.edu.sg

# Background:

Chronic kidney disease (CKD) is common in the elderly population. By 2035, approximately one-quarter of Singapore residents are expected to have CKD. Many of these patients are not referred to nephrologists.

# <u> Aim:</u>

We aimed to compare the characteristics of elderly ( $\geq$  65 years old) patients with stage 3B CKD and above in the referral and non-referral groups.

# **Design and settings**

A cross-sectional study in the primary care organisation National University Polyclinics (NUP), Singapore.

# Method:

Retrospective data were extracted from the electronic health records of CKD patients ( $\geq$  65

years old) with stage 3B CKD and above.

# Results:

From 1 January to 31 December 2018, a total of 1,536 patients aged 65 years or older were diagnosed with stage 3B CKD or above (non-referral group = 1,179 vs. referral group = 357). The mean patient age in the non-referral group (78.3 years) was older than that in the referral group (75.9 years) (P < 0.001). Indian elderly patients were referred more compared to their Chinese counterparts (P = 0.008). The non-referral group was prescribed significantly less fibrate, statins, insulin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and antiplatelet than the referral group (P < 0.05), but only the difference in fibrates remained significant on subsequent multivariate analysis.

# **Conclusions:**

This study demonstrates that there is a considerable number of elderly CKD patients exclusively managed in the primary care setting (n = 1,179) and that referrals primarily depend on demographic factors, namely age and ethnicity, rather than medical determinants of CKD severity or case complexity.

# Keywords:

CKD, elderly, primary health care, referral, nephrology, family medicine, population health.

#### How this fits in

This study reflects a vital role of family physicians in managing elderly CKD patients and highlights the need to review the referral process among this diverse group of patients. We recommend multidisciplinary collaboration between family physicians and nephrologists to refine the referral criteria to determine who truly needs early referrals to a nephrologist, and to develop guidelines to optimise the primary care management and monitoring of CKD patients, especially of those who are not referred and treated conservatively.

#### **Introduction**

Chronic kidney disease (CKD) is one of the common presentations among the older population in the primary care setting<sup>1–3</sup>. In the United States, the Third National Health and Nutrition Examination Survey (NHANES III) conducted between 1988 and 1994 demonstrated that 7.6% of individuals aged 60–69 years and 25.9% of those aged at least 75 years had a glomerular filtration rate (GFR) of 15–60 ml per minute per 1.73 m<sup>2</sup> compared to only 1.8% of those aged 40–59 years and 0.2% of those aged less than 40 years<sup>4</sup>. In France, an epidemiological survey of the Île-de-France area showed that the incidence rate among patients above 75 years was almost seven times that of patients aged 20–39 years (619 versus 92 new cases/million population) and more than double that of patients aged 40–59 years (619 versus 264 new cases/million population)<sup>5</sup>. In Singapore, it is projected that from 2007 to 2035, the number of residents with CKD will increase from 316,521 to 887,870, indicating an increase in prevalence from 12.2% to 24.3%<sup>6</sup>. By 2035, approximately one-quarter of Singapore residents are expected to have CKD. This trend will likely affect how we manage CKD patients in the primary care community<sup>6</sup>.

CKD management has become part of multi-chronic disease management for family physicians in Singapore. With the introduction of CKD classification by *Kidney Disease: Improving Global Outcomes* (KDIGO)<sup>7</sup>, the resultant increasing awareness of CKD among primary care settings had a significant impact on referral patterns to renal medical services with increased referral rates as reported in Boston, USA<sup>8</sup> and Brisbane, Australia<sup>9</sup>. However, comparative studies contrasting the characteristics of elderly CKD patients between referral and non-referral groups in the primary care setting are lacking.

In Singapore, National University Polyclinics (NUP) is the public primary care provider of the Western cluster health care system known as the National University Health System (NUHS). It offers subsidized family medical care services to communities in Western Singapore. In April 2017, the Holistic Approach in Lowering and Tracking CKD (HALT-CKD) programme was launched by the Ministry of Health, aiming to 1) recruit and track all patients with stage 1–4 CKD from any cause; 2) slow down CKD progression with control of risk factors and Renin Angiotensin System (RAS) blockade in all stages of CKD; and 3) encourage shared-care collaboration between primary health care and nephrologists at stage 3B–4 CKD<sup>10</sup>. This programme recommends that patients with stage 3B CKD or above be referred to nephrologists at secondary care hospitals. This is to provide the patients with early access to further investigations by nephrologists and preparation for renal replacement therapies to reduce morbidity, mortality and hospitalisation rates<sup>11,12</sup>. However, many elderly patients are

managed by the primary care team and are not referred to renal physicians. The factors contributing to the referral preferences are not well studied.

The objective of the study was to compare the characteristics of the elderly ( $\geq$  65 years) CKD 3B, 4, and 5 patients who were referred to nephrologists to those who were not referred at NUP in Singapore from 1 January 2018 until 31 December 2018. The null hypothesis is that there is no significant difference in CKD severity, socio-demographic factors, comorbidities, or medication between the referral and the non-referral groups.

# Methodology

We defined CKD as per the KDIGO classification<sup>7</sup>, and the elderly patients as those aged 65 years and above<sup>13</sup>. We collected retrospective data on all elderly patients with stage 3B CKD and above at five NUP polyclinics (Bukit Batok, Choa Chu Kang, Clementi, Jurong, and Pioneer) between 1 January 2018 and 31 December 2018 using the NUP electronic record system. As the CKD status can be confirmed only with two consecutive estimated GFRs (eGFR mL/min/1.73 m<sup>2</sup>) 90 days apart, data extraction was performed from 1 October 2017 until 31 December 2018. Estimated Glomerular Filtration Rate (eGFR) results are reported based on CKD-EPI Equation: Serum Creatinine ( $\mu$ mol/L), age (years), gender. Albuminuria-proteinuria categories were defined based on the albumin-to-creatinine ratio (ACR), and when not available, based on the protein-to-creatinine ratio (PCR), following the cut-off values of the KDIGO classification<sup>7</sup>: ACR < 3 mg/mmol or PCR < 15 mg/mmol – *Normal to mildly increased*; ACR of 3-30 mg/mmol or PCR of 15-50 mg/mmol – *Moderately increased*; ACR > 300 mg/mmol or PCR > 50 mg/mmol – *Severely increased*.

The inclusion criteria were as follows:

1. Patient age: ≥ 65 years

2. The stages of CKD in patients were confirmed when there were two eGFRs in mL/min/1.73 m<sup>2</sup> 90 days apart, defined as:

Stage 3B (eGFR: 30-44 mL/min/1.73 m<sup>2</sup>)

Stage 4 (eGFR: 15–29 mL/min/1.73 m<sup>2</sup>)

Stage 5 (eGFR: <15 mL/min/1.73 m<sup>2</sup>)

The exclusion criteria were as follows:

1. Patients with stages 1–3A CKD or an unknown CKD stage/status (lack of two consecutive eGFR results at least 90 days apart).

The following data was extracted from the electronic record for all eligible patients: demographics (age, sex, ethnicity, and smoking), comorbidities (diabetes mellitus, hypertension, dyslipidaemia, ischaemic heart disease, cerebrovascular disease, and peripheral vascular disease), and medications as of the date where CKD status was established [angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), statins, fibrates, biguanides, sulfonylureas, loop / potassium-sparing diuretics, insulin and antiplatelets].

We compared the characteristics of patients between those who were referred by the family physicians to nephrologists and those who were not.

Statistical analysis: We performed statistical analysis using STATA version 16.0 and R version 3.6.1. We used Chi-square tests for categorical variables; t-tests for continuous variables in bivariate comparisons between referral and non-referral groups; and two-way ANOVA to assess the mean number of comorbid diseases by age group in referral vs non-referral groups. In our further confirmatory analysis, we ran a stepwise logistic regression predicting referral with a first model containing only CKD status and albuminuria-proteinuria, as these two factors determine prognosis in the KDIGO classification<sup>7</sup>. The subsequent models included variables that were significant in the bivariate analysis, entered hierarchically by category (sociodemographic factors, comorbidities, medication). Missing values were handled by listwise deletion (we performed complete case analysis).

#### <u>Results</u>

From 1 January to 31 December 2018, a total of 1,536 patients aged 65 years or older were diagnosed with stage 3B or above CKD (Table 1). There were 1,179 patients in the non-referral group and 357 in the referral group. Data on blood pressure was missing in four participants (0.27% of the total sample). HbA1c data was missing in 50 out of 1,097 patients with diabetes mellitus (4.56%). Thirty-three patients (2.15% of the total sample) had a PCR but no ACR value: 19 patients (1.61%) of the non-referral group and 14 patients (3,92%) of the referral group. Values for both ACR and PCR were missing in 183 patients (11.91% of the total sample), 154 from the non-referral group (13.06%) and 29 from the referral group (8.12%).

The bivariate analysis indicated a significant difference in age between those who were not referred and those who were referred (means: 78.3 vs 75.9 years), regardless of age being coded as a continuous or a categorical variable (both P < 0.001). The Chi-square test was significant with respect to ethnicities (P = 0.017; Table 1). There was no significant difference between the non-referral and referral groups on CKD severity (Table 2) or comorbidities (Table

3). The groups differed for the following medications: fibrates, statins, insulin, sulforylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and antiplatelets (Table 4).

Logistic regression did not find significant associations between referrals and CKD status or albuminuria-proteinuria (Table 5). In Model 2, additionally testing socio-demographic variables, the older age groups, namely 80-84 years (OR: 0.43, P < 0.001), 85-89 years (OR: 0.49, P = 0.003), and  $\geq$  90 years (OR: 0.41, P = 0.015) were less likely to be referred than 65–69-year-olds. With respect to ethnicity, both Indians and the ethnicities grouped under "Others" had significantly higher odds to be referred than Chinese (resp. OR = 2.18 P = 0.008 and OR = 2.74 P = 0.007). These effects of age and ethnicity remained significant in Model 3, where medications were additionally included. However, of the drugs that were significant in the bivariate analysis, only fibrates remained weakly significant in the multivariate analysis (OR = 1.68, P = 0.049).

#### **Discussion**

#### Summary

This study demonstrates that primary care services such as NUP in Western Singapore manage a considerable number of elderly CKD patients instead of referrals to nephrologists (n = 1,179, 77%). It is noteworthy that the HALT-CKD programme's recommendation includes referral for patients with stage 3B CKD, which contrasts with the KDIGO guidelines that recommend referral to kidney specialists for patients who have stage 4 or 5 CKD<sup>14</sup>. However, our study showed that CKD severity or comorbidities may not contribute to patient referrals.

On the other hand, we found that patients above 80 years were less likely to be referred. Additionally, among ethnicities, Indian patients were more likely referred than Chinese patients. Other studies also highlighted age and ethnicities as possible implicit factors affecting treatment processes in healthcare management<sup>15,16</sup>. Differences in age groups and ethnicities may suggest underlying socio-cultural factors affecting patients' preferences and the family physician's beliefs, attitude and understanding in managing elderly CKD patients. In the case of age, the non-referral could arise from a shared decision made between the family physicians and the "older" elderly CKD patients to favour continued management in the community. Furthermore, language barriers may influence referrals, as most physicians at NUP are English-speaking and of Chinese ethnicity. Although English is the main language, the heterogenous socio-cultural backgrounds of Singaporean patients likely played a role in the dynamic interaction among elderly patients, their caregivers, and family physicians.

Bivariate analysis also suggested that more referral group patients were taking fibrates, statins, insulin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and antiplatelets than the non-referral group. However, only a weak difference in fibrates remained in the multivariate analysis. It is therefore possible that the initial bivariate differences found in medications were confounded by age. As the referral group of CKD patients was comparatively younger than the non-referral group, their chronic diseases were likely to be treated with more aggressive treatments.

#### Strengths and limitations

This study is one of the first retrospective cross-sectional studies to investigate elderly CKD patients enrolled in a single primary care organisation with a diverse mix of ethnicities in Southeast Asia. It highlights the role of age and ethnicity in the decision to refer elderly CKD patients to a nephrologist, demonstrating the real-life management of elderly CKD patients in the community.

Further qualitative studies to account for these differences are warranted to gain insights into the reasons underlying the decisions in the referral process involving primary care physicians, patients, and their families.

This study did not investigate whether the non-referral group could be further divided into subgroups, i.e., those who were already followed by a nephrologist before the study period, declined referral to a nephrologist, defaulted to hospital follow-ups, were discharged from the hospital and/or were treated at private health sectors. While duplicate follow-ups for CKD by NUP and nephrologists are likely avoided by most patients due to unnecessary costs, it cannot be excluded that more patients from older age groups have seen a nephrologist in the past, as they had likely had CKD for a longer time than the younger patients. Data collection was done in a cross-sectional manner over the course of one year and did not contain outcome data; future research into outcomes for those who are referred and those who are not referred would provide useful insights. We did not study changes in GFR or albuminuria-proteinuria. Finally, data on both ACR and PCR was missing in approximately one tenth of the sample, which reduced the power of the analyses to detect differences in albuminuria-proteinuria.

# Comparing with existing literature

Torreggiani et al. 2021 showed that 70% of their hospital renal clinic outpatients were aged 60 and above and 25% were aged 80 or older<sup>17</sup>. However, in their study, only approximately 50% of these patients had stage 3B CKD or above<sup>17</sup>. This contrasts with our study population, where the NUP local guidelines do not recommend referral to a nephrologist below stage 3B. Torreggiani et al. 2021 also revealed that the majority of the causes of CKD are multifactorial diseases, nephroangiosclerosis, and diabetes-associated kidney disease, particularly the

variant with low proteinuria (diabetes-vascular), which increases with age<sup>17</sup>. This variant accounts for over 80% of the diagnoses in patients aged 80 or older. Unlike outpatient nephrologist clinics, where causes of kidney diseases can be confirmed using hospital diagnostic support such as renal biopsy and imaging, almost all CKD patients in primary care in Singapore are diagnosed biochemically and with an ultrasound scan to rule out underlying obstructive nephropathy.

Conservative management of CKD is gradually recognised as a viable therapeutic alternative for patients with advanced CKD<sup>18,19</sup>. Early detection leads to early management of the associated risk factors to optimise medical care in the elderly population<sup>5,6</sup>. Most of these risk factors can be identified and managed in the primary care setting. In the United Kingdom, Mclure retrospectively studied 124 patients in the hospital setting who were  $\geq$  80 years of age and had stage 4 (115 patients) or 5 (9 patients) CKD<sup>20</sup>. Forty-seven percent of their patients were discharged to the primary care with median time to death being 3.57 years vs 2.66 years for those who remained in the nephrologist follow-up. This study suggests that the majority of elderly patients can be safely and appropriately managed in the primary care setting.

However, there are reported challenges that affect the delivery of CKD care in primary care<sup>21</sup>. These include suboptimal screening/monitoring of CKD risk factors<sup>22,23</sup>, infrequent discussions between providers and patients regarding CKD<sup>20</sup>, suboptimal albuminuria testing<sup>23,24</sup>, suboptimal blood pressure control<sup>23</sup>, suboptimal renin-angiotensin blockade in CKD patients with proteinuria<sup>25,26</sup>, limited knowledge of CKD risk factors<sup>27,28</sup> and poor awareness of Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines<sup>29–32</sup>. Our study shows that 381 (33%) of patients in the non-referral group and 106 (30%) of patients in the referral group were not prescribed a reno-protective ACEI or ARB. This may be explained by the average blood pressure readings of respectively 133/67 mmHg and 134/68 mmHg in the two groups (Table 3). Lowering blood pressure further could be contraindicated in these elderly groups of patients. However, among the diabetic elderly CKD patients, the diabetic control was good, with both groups showing HbA1c < 8.0% (Table 3).

#### Implications for Research and/or practice

This study highlights that family physicians at NUP managed 77% of the total elderly CKD patients with stage 3B, 4 and 5 diseases. This reflects a vital role of family physicians in managing the elderly with severe CKD. This study highlights the need to review the referral process in this diverse group of patients and to better understand the role of socio-demographic factors in this context. We recommend multidisciplinary collaboration between family physicians and nephrologists to refine the referral criteria to detect patients who truly need early referrals to nephrologists and to develop guidelines to optimise primary care

management and monitoring of CKD patients, especially for those who are not referred and treated conservatively.

**Funding:** The research was funded by the NUHS Primary Care Physician Research Development Seed Fund in 2020.

**Disclosure statement**: No potential competing interest was reported by the authors.

**Ethics:** Ethics approval was obtained from the ethics committee of the Domain Specific Review Board of the National Healthcare Group.

# Acknowledgements

We thank Miss Sharifah Nur Mohamed Shariff from the Department of Family Medicine Development, National University Polyclinics, for her invaluable help with data extraction.

A CONTRACTION OF CONTRACTICO OF CONT

 Table 1. Patient demographics

rable 1. Patient demographics	5	4	5	
	Non-referral group	Referral group	P value	
Sex (n(%))		C		
Female	621 (52.67)	188 (52.66)		
Male	558 (47.33)	169 (47.34)	0.997	
Age group (n(%))		S.		
65–69	167 (14.16)	77 (21.57)		
70–74	226 (19.17)	74 (20.73)		
75–79	258 (21.88)	107 (29.97)		
80–84	267 (22.65)	52 (14.57)		
85–89	177 (15.01)	35 (9.80)		
90+	84 (7.12)	12 (3.36)	<0.001	
Age (mean (SD))	78.35 (7.51)	75.88 (6.83)	<0.001	
Ethnicity (n(%))				
Chinese	907 (76.93)	250 (70.03)		
Indian	48 (4.07)	21 (5.88)		
Malay	204 (17.30)	72 (20.17)		
Others	20 (1.70)	14 (3.92)	0.017	
Smoking status (n(%))	Q			
Ex-smoker	39 (3.31)	16 (4.48)		
Non-smoker	1,089 (92.37)	317 (88.80)		
Current smoker	51 (4.33)	24 (6.72)	0.097	

5

\*P value is taken from chi-square test for categorical, and t-test for continuous variables.

in the form of the

**Table 2.** Comparison of indicators of CKD severity (CKD status and albuminuria-proteinuria)

 of non-referral and referral groups

	Non-referral	Referral group	
	group (n(%))	(n(%))	P value
CKD status		N	
CKD 3B	856 (72.60)	249 (69.75)	
CKD 4	279 (23.66)	96 (26.89)	
CKD 5	44 (3.73)	12 (3.36)	0.453
		$\sim$	
Albuminuria-proteinuria*	C		
Normal to mildly increased	290 (74.94)	97 (25.06)	
Moderately increased	402 (78.67) 109 (21.33)		
Severely increased	333 (73.19)	122 (26.81)	0.126

P value is taken from chi-square tests.

\*Albuminuria-proteinuria data (ACR or PCR) was available for 1353 patients, 1025 in the nonreferral and 328 in the referral group.

Non-referral group	Referral group	P value	
	(	3	
837 (70.99)	260 (72.83)	0.544	
1,165 (98.81)	348 (97.48)	0.117	
1,155 (98.00)	351 (98.30)	0.837	
233 (19.80)	65 (18.21)	0.566	
296 (25.11)	91 (25.49)	0.939	
93 (7.89)	25 (7.00)	0.662	
268 (22.73)	72 (20.17)	0.343	
93 (7.89)	25 (7.00)	0.662	
$\mathcal{O}$	5		
4.51 (1.01)	4.46 (1.00)	0.443	
noses by age group (r	nean (SD))		
4.54 (1.01)	4.34 (1.01)	0.136	
4.48 (1.01)	4.61 (1.01)	0.352	
4.55 (1.01)	4.41 (1.01)	0.218	
4.52 (1.01)	4.31 (1.01)	0.172	
4.50 (1.01)	4.71 (1.01)	0.258	
4.39 (1.01)	4.83 (1.01)	0.158	
133.33 (16.24)	134.17 (14.54)	0.357	
67.71 (9.41)	68.55 (8.94)	0.125	
7.35 (1.34)	7.46 (1.46)	0.261	
	837 (70.99) 1,165 (98.81) 1,155 (98.00) 233 (19.80) 296 (25.11) 93 (7.89) 268 (22.73) 93 (7.89) 4.51 (1.01) 4.51 (1.01) 4.54 (1.01) 4.54 (1.01) 4.55 (1.01) 4.55 (1.01) 4.52 (1.01) 4.50 (1.01) 4.39 (1.01) 133.33 (16.24) 67.71 (9.41)	837 (70.99) $260 (72.83)$ $1,165 (98.81)$ $348 (97.48)$ $1,155 (98.00)$ $351 (98.30)$ $233 (19.80)$ $65 (18.21)$ $296 (25.11)$ $91 (25.49)$ $93 (7.89)$ $25 (7.00)$ $268 (22.73)$ $72 (20.17)$ $93 (7.89)$ $25 (7.00)$ $4.51 (1.01)$ $4.46 (1.00)$ <b>moses by age group (mean (SD))</b> $4.54 (1.01)$ $4.34 (1.01)$ $4.48 (1.01)$ $4.61 (1.01)$ $4.55 (1.01)$ $4.41 (1.01)$ $4.52 (1.01)$ $4.31 (1.01)$ $4.50 (1.01)$ $4.71 (1.01)$ $4.39 (1.01)$ $4.83 (1.01)$ $133.33 (16.24)$ $134.17 (14.54)$ $67.71 (9.41)$ $68.55 (8.94)$	

Table 3. Comparison of patient comorbidities between non-referral and referral groups.

P value is taken from chi-square test for categorical, unpaired t-test for continuous variables, and two-way ANOVA for the mean number of comorbid diagnoses by age group.

\*Blood pressure data available for 1,532 patients, 1,177 in non-referral and 355 in referral group

\*\*HbA1c data available for 1,047/1,097 diabetes mellitus patients, 795 in non-referral and 252 in referral group

	Non-referral grou	ıp,	Р			
	n (%)	Referral group, n (%)	value			
Drugs		×.				
Fibrates	55 (4.66)	28 (7.84)	0.020			
Statins	959 (81.34)	311 (87.11)	0.012			
Insulin	187 (15.86)	76 (21.29)	0.017			
Biguanides	281 (23.83)	88 (24.65)	0.752			
Sulfonylureas	331 (28.07)	123 (34.45)	0.021			
DPP4	184 (15.61)	79 (22.13)	0.004			
ARB	435 (36.90)	144 (40.34)	0.24			
ACEI	363 (30.79)	107 (29.97)	0.769			
ССВ	472 (62.5)	707 (60.00)	0.433			
Loop-diuretics	302 (25.61)	95 (26.61)	0.707			
Potassium Sparing Diuretic	28 (2.37)	5 (1.40)	0.266			
Alpha-blocker	42 (3.56)	6 (1.68)	0.073			
Beta-blocker	490 (41.56)	157 (43.98)	0.418			
Antiplatelets	408 (34.61)	147 (41.18)	0.024			

Table 4. Comparisons of patient medications between non-referral and referral groups.

n chi-square tes.

**Table 5** Logistic regression predicting likelihood of referral with all variables significant in the bivariate analysis

					×.		
	Model 1		Model 2			Model 3	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	
CKD severity				(			
CKD status					V		
CKD_catG3b	Ref.		Ref.	$\cap$	Ref.		
CKD_catG4	1.23 (0.92-1.63)	0.162	1.30 (0.97-1.74)	0.081	1.30 (0.97-1.74)	0.085	
CKD_catG5	1.02 (0.53-2.00)	0.943	0.99 (0.50-1.96)	0.977	0.98 (0.49-1.96)	0.961	
				CR			
Albuminuria-proteinuria							
Normal to mildly							
increased	Ref.		Ref.	<b>D</b>	Ref.		
Moderately increased	0.82 (0.60-1.12)	0.201	0.89 (0.64-1.22)	0.243	0.87 (0.63-1.21)	0.410	
Severely increased	1.11 (0.81-1.51)	0.518	1.18 (0.86-1.6 <b>2</b> )	0.318	1.14 (0.83-1.58)	0.417	
			2				
Socio-demographics			0				
Age group							
65-69 years			Ref.		Ref.		
70-74 years			0.75 (0.51-1.13)	0.168	0.77 (0.52-1.16)	0.208	
75-79 years			0.97 (0.66-1.41)	0.856	1.01 (0.69-1.48)	0.962	
80-84 years		4	0.43 (0.28-0.67)	<0.001***	0.47 (0.30-0.73)	<0.001***	
85-89 years		CI	0.49 (0.30-0.79)	0.003**	0.56(0.34-0.91)	0.020*	
90 years and older			0.41 (0.20-0.84)	0.015*	0.48 (0.23-0.99)	0.046*	
		2					
Ethnicity		5					
Chinese			Ref.		Ref.		
Indian			2.18 (1.23-3.86)	0.008**	2.07 (1.16-3.70)	0.014*	
Malay	Č		1.23 (0.88-1.70)	0.223	1.21 (0.87-1.68)	0.268	
Others		2	2.74 (1.32-5.70)	0.007**	2.82 (1.35-5.89)	0.006**	
	5						
Medication							
Fibrates	S				1.69 (1.00-2.83)	0.049	
Statins	5				1.35 (0.91-2.00)	0.141	
Insulin	0				1.01 (0.72-1.43)	0.935	
Sulfonylureas	07				1.15 (0.85-1.54)	0.365	
DPP4					1.20 (0.85-1.71)	0.295	
Antiplatelets	2				1.23 (0.94-1.60)	0.131	
	te the odds of be	eina referra	ed Legend <sup>.</sup> *<0	05. **<0.01			

Results indicate the odds of being referred. Legend: \*<0.05; \*\*<0.01 \*\*\*< 0.001

Accel

References:

1. Anderson S, Halter JB, Hazzard WR, et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. *J Am Soc Nephrol JASN*. 2009;20(6):1199-1209. doi:10.1681/ASN.2008080860

2. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with endstage renal disease in the United States to the year 2010. *J Am Soc Nephrol JASN*. 2001;12(12):2753-2758.

3. Locatelli F, Pozzoni P. Chronic kidney disease in the elderly: is it really a premise for overwhelming renal failure? *Kidney Int*. 2006;69(12):2118-2120. doi:10.1038/sj.ki.5001547

4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis Off J Natl Kidney Found*. 2003;41(1):1-12. doi:10.1053/ajkd.2003.50007

5. Jungers P, Chauveau P, Descamps-Latscha B, et al. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 1996;11(8):1542-1546.

6. Wong LY, Liew AST, Weng WT, Lim CK, Vathsala A, Toh MPHS. Projecting the Burden of Chronic Kidney Disease in a Developed Country and Its Implications on Public Health. *Int J Nephrol.* 2018;2018:1-9. doi:10.1155/2018/5196285

7. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements. 2013 Jan 1;3(1):1-50.

8. Singh K, Waikar SS, Samal L. Evaluating the feasibility of the KDIGO CKD referral recommendations. *BMC Nephrol*. 2017;18(1):223. doi:10.1186/s12882-017-0646-y

9. Noble E, Johnson DW, Gray N, et al. The impact of automated eGFR reporting and education on nephrology service referrals. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2008;23(12):3845-3850. doi:10.1093/ndt/gfn385

10. Kwek JL, Kee TYS. World Kidney Day 2020: Advances in Preventive Nephrology. *Ann Acad Med Singapore*. 2020;49(4):175-179.

11. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. *Am J Med*. 2011;124(11):1073-1080.e2. doi:10.1016/j.amjmed.2011.04.026

12. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. *Cochrane Database Syst Rev.* 2014;(6):CD007333. doi:10.1002/14651858.CD007333.pub2

13. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of "elderly." *Geriatr Gerontol Int.* 2006;6(3):149-158. doi:10.1111/j.1447-0594.2006.00341.x

14. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and

management of chronic kidney disease. *Kidney Int Suppl*. 2013;3(1):1-150. doi:10.1038/kisup.2012.73

15. Giasson HL, Chopik WJ. Geographic patterns of implicit age bias and associations with state-level health outcomes across the United States. *Eur J Soc Psychol.* 2020;50(6):1173-1190. doi:10.1002/ejsp.2707

16. Hall WJ, Chapman MV, Lee KM, et al. Implicit Racial/Ethnic Bias Among Health Care Professionals and Its Influence on Health Care Outcomes: A Systematic Review. *Am J Public Health*. 2015;105(12):e60-e76. doi:10.2105/AJPH.2015.302903

17. Torreggiani M, Chatrenet A, Fois A, et al. Elderly Patients in a Large Nephrology Unit: Who Are Our Old, Old-Old and Oldest-Old Patients? *J Clin Med*. 2021;10(6). doi:10.3390/jcm10061168

18. Treit K, Lam D, O'Hare AM. Timing of dialysis initiation in the geriatric population: toward a patient-centered approach. *Semin Dial*. 2013;26(6):682-689. doi:10.1111/sdi.12131

19. Johnson DS, Kapoian T, Taylor R, Meyer KB. Going Upstream: Coordination to Improve CKD Care. *Semin Dial*. 2016;29(2):125-134. doi:10.1111/sdi.12461

20. McClure M, Jorna T, Wilkinson L, Taylor J. Elderly patients with chronic kidney disease: do they really need referral to the nephrology clinic? *Clin Kidney J*. 2017;10(5):698-702. doi:10.1093/ckj/sfx034

21. Abdel-Kader K, Greer RC, Boulware LE, Unruh ML. Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study. *BMC Nephrol*. 2014;15:64. doi:10.1186/1471-2369-15-64

22. Greer RC, Cooper LA, Crews DC, Powe NR, Boulware LE. Quality of patientphysician discussions about CKD in primary care: a cross-sectional study. *Am J Kidney Dis Off J Natl Kidney Found*. 2011;57(4):583-591. doi:10.1053/j.ajkd.2010.08.027

23. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD. Primary care management of chronic kidney disease. *J Gen Intern Med*. 2011;26(4):386-392. doi:10.1007/s11606-010-1523-6

24. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic. *Am J Kidney Dis Off J Natl Kidney Found*. 2007;49(5):634-641. doi:10.1053/j.ajkd.2007.02.258

25. Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A. Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. *Am J Kidney Dis Off J Natl Kidney Found*. 2007;50(5):733-742. doi:10.1053/j.ajkd.2007.08.004

26. Philipneri MD, Rocca Rey LA, Schnitzler MA, et al. Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. *Clin Exp Nephrol.* 2008;12(1):41-52. doi:10.1007/s10157-007-0016-3

27. Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference? *Am J Kidney Dis Off J Natl Kidney Found*. 2006;47(1):72-77. doi:10.1053/j.ajkd.2005.09.027

28. Lenz O, Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey. *BMC Med*. 2006;4:30. doi:10.1186/1741-7015-4-30

29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis Off J Natl Kidney Found*. 2002;39(2 Suppl 1):S1-266.

30. Greer RC, Powe NR, Jaar BG, Troll MU, Boulware LE. Effect of primary care physicians' use of estimated glomerular filtration rate on the timing of their subspecialty referral decisions. *BMC Nephrol.* 2011;12:1. doi:10.1186/1471-2369-12-1

31. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: a national study. *Am J Kidney Dis Off J Natl Kidney Found*. 2006;48(2):192-204. doi:10.1053/j.ajkd.2006.04.073

32. Agrawal V, Ghosh AK, Barnes MA, McCullough PA. Awareness and knowledge of clinical practice guidelines for CKD among internal medicine residents: a national online survey. *Am J Kidney Dis Off J Natl Kidney Found*. 2008;52(6):1061-1069. doi:10.1053/j.ajkd.2008.06.022

Solution of the second second